GenPath logo in conjunction with oncology

Meet Our Experts

James Weisberger, MD, FACP, FASCP

Chief Medical Officer, Executive Vice President, Laboratory Director

Dr. Weisberger is a board certified anatomic and clinical pathologist and recognized leader in hematopathology. He oversees all key laboratory operations and quality systems, and maintains BioReference Laboratories as an innovative, quality laboratory where patient care and laboratory safety come first. Dr. Weisberger strives to position BioReference as a leader in providing patient-centric, precision-based laboratory results and data analytics for best practice of patient care.

Dr. James Weisberger has authored more than 40 publications as abstracts or peer-reviewed journal articles, and is an active educator at the New York Medical College, where he serves as a Clinical Associate Professor of Pathology and Medicine. He is a Fellow and Member of the New Jersey House of Delegates for the College of American Pathology, and a Fellow of the American Society of Clinical Pathology. He is also a member of the New Jersey Society of Pathology and Association for Molecular Pathology. Dr. Weisberger was Chief Resident in Pathology at Westchester Medical Center and holds both a BS and MS from Stanford University, and an MD from the University of Pennsylvania.

Bevan Tandon, MD

Director of Cancer Genomics

Dr. Tandon holds American Board of Pathology subspecialty board certifications in both molecular genetic pathology, and also hematopathology. His general certifications are in anatomic and clinical pathology. Dr. Tandon’s training in hematopatholgy consisted of an intensive fellowship and clinical instructorship at the University of Pittsburgh School of Medicine, under the guidance of WHO lead author Dr. Steven Swerdlow. His training in molecular genetic pathology was conducted at Washington University in St. Louis School of Medicine. Dr. Tandon completed his general residency training at Northwestern University Feinberg School of Medicine. Dr. Tandon is an active member of the Society for Hematopathology and the Association for Molecular Pathology.

Eric Antoniou, PhD

Assistant Director, Cancer Genomics

Dr. Antoniou earned his PhD from the University of Bordeaux, France. He was formerly the senior manager of Cold Spring Harbor Laboratory genome sequencing center. He also held management positions at Ginkgo Bioworks and The Jackson Laboratory. Prior to these positions, he was an Assistant Professor at the University of Missouri-Columbia. Dr. Antoniou has eighteen years of experience in genomics science, including nine years in next-generation sequencing.

Zhixiong Xu, PhD, FACMG

Director, Cancer Cytogenetics

Zhixiong Xu is ABMGG-certified in clinical molecular genetics and clinical cytogenetics. He joined GeneDx in 2013 and served as Assistant Director of the Hereditary Cancer program. He received his BS in Biological Chemistry from Xiamen University and his PhD in Cell Biology from the Peking Union Medical College. He completed a postdoctoral fellowship in molecular oncology and was appointed Research Assistant Professor at the Vanderbilt-Ingram Cancer Center. While at the National Institutes of Health (NIH), he worked with Gary Felsenfeld in genetic and epigenetic regulation of gene expression and completed his medical genetics fellowship training at the National Human Genome Research Institute (NHGRI). Dr. Xu was a recipient of the Hope Street Kids Fellowship Award and the American Society of Hematology Scholar Award.

Xiaoling Guo, MD, PhD

Molecular Pathologist, Cancer Genomics

Dr. Xiaoling Guo is a board certified pathologist trained in anatomic and clinical pathology with subspecialty fellowship training in molecular genetics pathology. Dr. Guo is a graduate of the MD/PhD program at Albert Einstein College of Medicine. She completed residency and fellowship at Yale New Haven Hospital. Prior to joining BioReference laboratories, she worked as a surgical pathologist and co-director of the Molecular Pathology Laboratory at Montefiore Medical Center for close to four years. Her long-term research interest is in molecular markers in cancer diagnosis, prognosis, and treatment.